Cantor Fitzgerald initiated coverage on Innoviva
$INVA
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2025 | $17.00 | Sell | Goldman |
| 8/11/2025 | $45.00 | Outperform | Oppenheimer |
| 7/14/2025 | $40.00 | Buy | H.C. Wainwright |
| 7/11/2025 | $26.00 | Overweight | Cantor Fitzgerald |
| 3/7/2025 | $55.00 | Sector Outperform | Scotiabank |
| 6/18/2024 | Overweight | Cantor Fitzgerald | |
| 7/20/2022 | $16.00 | Neutral | Goldman |
| 2/23/2022 | $10.00 → $12.00 | Underweight | Morgan Stanley |
10-Q - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
Goldman initiated coverage of Innoviva with a rating of Sell and set a new price target of $17.00
Oppenheimer initiated coverage of Innoviva with a rating of Outperform and set a new price target of $45.00
H.C. Wainwright initiated coverage of Innoviva with a rating of Buy and set a new price target of $40.00
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five countries. NUZOLVENCE is one of the first new treatments approved by the FDA for uncomplicated urogenital gonorrhea in nearly two decades. Gonorrhea affects more than 82 million people worldwide each year and is the second most reported bacterial STI in the United States.1,2 Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority pathogen. Gonorrhea is the second most reported bacterial STI in the United States, with resistance to first-line treatment emerging.1,2 Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced the publication of positive res
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 2, 2025 at 4:30 p.m. Eastern Time. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. An archived replay
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v
Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achieve
Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,
Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA® (ceftobiprole) progressing as planned Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today rep
SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)
SC 13G - Innoviva, Inc. (0001080014) (Subject)
SC 13D - Innoviva, Inc. (0001080014) (Subject)